Kory James Wentworth Entrada Therapeutics, Inc. (TRDA) insider trading activity

Kory James Wentworth is Chief Financial Officer of Entrada Therapeutics, Inc.. Currently has a direct ownership of 111,320 shares of TRDA, which is worth approximately $1.19 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 4,929 shares (Common Stock) at a price of $11.68 per share, resulting in proceeds of $57,570. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 111K

50.74% 3M change

50.09% 12M change

Total Value Held $1.19 Million

KORY JAMES WENTWORTH Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Payment of exercise price or tax liability	$57,570 $11.68 p/Share	4,929 Reduced 4.24%	111,320 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	42,400 Added 26.73%	116,249 Common Stock
Dec 02 2024	SELL Open market or private sale	$100,000 $20.0 p/Share	5,000 Reduced 6.34%	73,849 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$10,500 $2.1 p/Share	5,000 Added 5.96%	78,849 Common Stock
Nov 29 2024	SELL Open market or private sale	$19,970 $19.97 p/Share	1,000 Reduced 1.34%	73,849 Common Stock
Nov 29 2024	BUY Exercise of conversion of derivative security	$2,100 $2.1 p/Share	1,000 Added 1.32%	74,849 Common Stock
Nov 11 2024	SELL Open market or private sale	$172,567 $19.98 p/Share	8,637 Reduced 10.47%	73,849 Common Stock
Nov 11 2024	BUY Exercise of conversion of derivative security	$12,600 $2.1 p/Share	6,000 Added 6.78%	82,486 Common Stock
Sep 09 2024	SELL Open market or private sale	$47,829 $14.97 p/Share	3,195 Reduced 4.01%	76,486 Common Stock
Sep 05 2024	SELL Payment of exercise price or tax liability	$2,496 $15.13 p/Share	165 Reduced 0.21%	79,681 Common Stock
Sep 04 2024	SELL Payment of exercise price or tax liability	$14,510 $15.42 p/Share	941 Reduced 1.16%	79,846 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$10,500 $16.8 p/Share	625 Reduced 0.77%	80,787 Common Stock
Jul 08 2024	SELL Open market or private sale	$26,282 $14.95 p/Share	1,758 Reduced 2.11%	81,412 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	$18,900 $2.1 p/Share	9,000 Added 9.76%	83,170 Common Stock
Mar 06 2024	SELL Open market or private sale	$50,298 $12.31 p/Share	4,086 Reduced 5.22%	74,170 Common Stock
Mar 05 2024	SELL Payment of exercise price or tax liability	$18,063 $12.28 p/Share	1,471 Reduced 1.85%	78,256 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$9,597 $12.9 p/Share	744 Reduced 0.92%	79,727 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	30,900 Added 27.75%	80,471 Common Stock
Dec 26 2023	SELL Open market or private sale	$1,566 $16.67 p/Share	94 Reduced 0.19%	49,571 Common Stock
Dec 26 2023	BUY Exercise of conversion of derivative security	$197 $2.1 p/Share	94 Added 0.19%	49,665 Common Stock
Dec 22 2023	SELL Open market or private sale	$161,867 $15.86 p/Share	10,206 Reduced 17.07%	49,571 Common Stock
Dec 22 2023	BUY Exercise of conversion of derivative security	$21,432 $2.1 p/Share	10,206 Added 14.58%	59,777 Common Stock
Dec 21 2023	SELL Open market or private sale	$33,154 $15.07 p/Share	2,200 Reduced 4.25%	49,571 Common Stock
Dec 21 2023	BUY Exercise of conversion of derivative security	$4,620 $2.1 p/Share	2,200 Added 4.08%	51,771 Common Stock
Sep 06 2023	SELL Open market or private sale	$13,053 $13.74 p/Share	950 Reduced 1.88%	49,571 Common Stock

KJW

Kory James Wentworth

Chief Financial Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Value

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA

Account